Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by analysts at Janney Montgomery Scott from a “neutral” rating to a “buy” rating in a note issued to investors on Monday, Marketbeat.com reports. The firm currently has a $47.00 price objective on the specialty pharmaceutical company’s stock. Janney Montgomery Scott’s price target would indicate a potential upside of 26.51% from the company’s previous close.

Several other equities research analysts have also commented on SUPN. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Piper Jaffray Companies reiterated a “hold” rating and issued a $45.00 price objective on shares of Supernus Pharmaceuticals in a research note on Friday, September 8th. Cantor Fitzgerald reiterated a “buy” rating and issued a $49.00 price objective on shares of Supernus Pharmaceuticals in a research note on Tuesday, September 19th. Stifel Nicolaus lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 price objective for the company. in a research note on Tuesday, September 19th. They noted that the move was a valuation call. Finally, Jefferies Group reiterated a “buy” rating and issued a $51.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $49.60.

Supernus Pharmaceuticals (NASDAQ:SUPN) traded down $0.05 during trading hours on Monday, reaching $37.15. 465,433 shares of the company’s stock traded hands, compared to its average volume of 609,007. The stock has a market cap of $1,960.00, a price-to-earnings ratio of 35.09, a price-to-earnings-growth ratio of 1.57 and a beta of 1.19. Supernus Pharmaceuticals has a 52-week low of $21.50 and a 52-week high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The firm had revenue of $80.40 million during the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The business’s revenue for the quarter was up 41.5% on a year-over-year basis. equities research analysts expect that Supernus Pharmaceuticals will post 1.07 earnings per share for the current year.

In other news, CFO Gregory S. Patrick sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $47.60, for a total transaction of $2,380,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Padmanabh P. Bhatt sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $49.86, for a total transaction of $249,300.00. Following the sale, the senior vice president now owns 12,500 shares of the company’s stock, valued at approximately $623,250. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 150,000 shares of company stock valued at $7,055,350. 6.70% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of SUPN. Vanguard Group Inc. increased its stake in shares of Supernus Pharmaceuticals by 39.1% during the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after purchasing an additional 984,200 shares during the last quarter. Pictet Asset Management Ltd. increased its stake in shares of Supernus Pharmaceuticals by 438.7% during the 3rd quarter. Pictet Asset Management Ltd. now owns 491,283 shares of the specialty pharmaceutical company’s stock worth $19,651,000 after purchasing an additional 400,083 shares during the last quarter. Hodges Capital Management Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $17,220,000. Scout Investments Inc. increased its stake in shares of Supernus Pharmaceuticals by 239.5% during the 3rd quarter. Scout Investments Inc. now owns 565,900 shares of the specialty pharmaceutical company’s stock worth $22,636,000 after purchasing an additional 399,225 shares during the last quarter. Finally, Rice Hall James & Associates LLC increased its stake in shares of Supernus Pharmaceuticals by 24.5% during the 2nd quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock worth $58,675,000 after purchasing an additional 267,971 shares during the last quarter. Institutional investors own 98.34% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/04/supernus-pharmaceuticals-supn-raised-to-buy-at-janney-montgomery-scott.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.